Syk

From Wikipedia, the free encyclopedia
Jump to: navigation, search
For the school abbreviated SYK, see Helsingin Suomalainen Yhteiskoulu.
SYK
Protein SYK PDB 1a81.png
Available structures
PDB Ortholog search: PDBe RCSB
Identifiers
Aliases SYK, p72-Syk, spleen tyrosine kinase, spleen associated tyrosine kinase
External IDs OMIM: 600085 MGI: 99515 HomoloGene: 2390 GeneCards: SYK
Genetically Related Diseases
type 2 diabetes mellitus, multiple sclerosis, vascular dementia[1]
RNA expression pattern
PBB GE SYK 209269 s at fs.png

PBB GE SYK 207540 s at fs.png
More reference expression data
Orthologs
Species Human Mouse
Entrez
Ensembl
UniProt
RefSeq (mRNA)

NM_001135052
NM_001174167
NM_001174168
NM_003177

NM_001198977
NM_011518

RefSeq (protein)

NP_001128524
NP_001167638
NP_001167639
NP_003168

NP_001185906.1
NP_035648.2
NP_001185906
NP_035648

Location (UCSC) Chr 9: 90.8 – 90.9 Mb Chr 13: 52.58 – 52.65 Mb
PubMed search [2] [3]
Wikidata
View/Edit Human View/Edit Mouse

Spleen tyrosine kinase, also known as Syk, is an enzyme which in humans is encoded by the SYK gene.[4][5][6]

Function[edit]

SYK, along with Zap-70, is a member of the Syk family of tyrosine kinases. These non-receptor cytoplasmic tyrosine kinases share a characteristic dual SH2 domain separated by a linker domain.[7]

While Syk and Zap-70 are primarily expressed in hematopoietic tissues, there is expression of Syk in a variety of tissues. Within B and T cells respectively, Syk and Zap-70 transmit signals from the B-Cell receptor and T-Cell receptor.[7] Syk plays a similar role in transmitting signals from a variety of cell surface receptors including CD74, Fc Receptor, and integrins.

Function during development[edit]

Mice that lack Syk completely (Syk−/−, Syk-knockout) die during embryonic development around midgestation. They show severe defects in the development of the lymphatic system. Normally, the lymphatic system and the blood system are strictly separated from each other. However, in Syk deficient mice the lymphatics and the blood vessels form abnormal shunts, leading to leakage of blood into the lymphatic system. The reason for this phenotype was identified by a genetic fate mapping approach, showing that Syk is expressed in myeloid cells which orchestrate the proper separation of lymphatics and blood system during embryogenesis and beyond. Thus, Syk is an essential regulator of the lymphatic system development in mice.[8]

Clinical significance[edit]

Abnormal function of Syk has been implicated in several instances of hematopoeitic malignancies including translocations involving Itk and Tel. Constitutive Syk activity can transform B cells.[7] Several transforming viruses contain "Immunoreceptor Tyrosine Activation Motifs" (ITAMs) which lead to activation of Syk including Epstein Barr virus, bovine leukemia virus, and mouse mammary tumor virus.

SYK inhibition[edit]

Given the central role of SYK in transmission of activating signals within B-cells, a suppression of this tyrosine kinase might aid in the treatment of B cell malignancies and autoimmune diseases.[7]

Syk inhibition has been proposed as a therapy for both lymphoma and chronic lymphocytic leukemia.[7] Syk inhibitors are in clinical development, including GS-9973 [7] now named entospletinib.[9] Other inhibitors of B-cell receptor (BCR) signaling including ibrutinib (PCI-32765) which inhibits BTK,[10] and idelalisib (PI3K inhibitor - CAL-101 / GS-1101) showed activity in the diseases as well.[11]

The orally active SYK inhibitor fostamatinib (R788) in the treatment of rheumatoid arthritis.[12]

Epithelial malignancies[edit]

The role of Syk in epithelial malignancies is controversial. Several authors have suggested that abnormal Syk function facilitates transformation in Nasopharyngeal carcinoma and head and neck cancer while other authors have suggested a tumor suppressor role in breast and gastric cancer.

Without Syk, the protein it makes, and genetic disruption in a panel of 55 genes thought also to be controlled by Syk, breast ductal carcinoma in situ (breast DCIS, which can become invasive), it is believed that the cancer has a markedly increased tendency to invade and metastasize.[13]

Interactions[edit]

Syk has been shown to interact with:

References[edit]

  1. ^ "Diseases that are genetically associated with SYK view/edit references on wikidata". 
  2. ^ "Human PubMed Reference:". 
  3. ^ "Mouse PubMed Reference:". 
  4. ^ "Entrez Gene: SYK Spleen tyrosine kinase". 
  5. ^ Chan AC, Iwashima M, Turck CW, Weiss A (November 1992). "ZAP-70: a 70 kd protein-tyrosine kinase that associates with the TCR zeta chain". Cell. 71 (4): 649–62. doi:10.1016/0092-8674(92)90598-7. PMID 1423621. 
  6. ^ Ku G, Malissen B, Mattei MG (1994). "Chromosomal location of the Syk and ZAP-70 tyrosine kinase genes in mice and humans". Immunogenetics. 40 (4): 300–2. doi:10.1007/BF00189976. PMID 8082894. 
  7. ^ a b c d e f Seda V, Mraz M (March 2015). "B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells". European Journal of Haematology. 94 (3): 193–205. doi:10.1111/ejh.12427. PMID 25080849. 
  8. ^ Böhmer R, Neuhaus B, Bühren S, Zhang D, Stehling M, Böck B, Kiefer F (March 2010). "Regulation of developmental lymphangiogenesis by Syk(+) leukocytes". Developmental Cell. 18 (3): 437–49. doi:10.1016/j.devcel.2010.01.009. PMID 20230750. 
  9. ^ Sharman J, Di Paolo J (2016). "Targeting B-cell receptor signaling kinases in chronic lymphocytic leukemia: the promise of entospletinib". Therapeutic Advances in Hematology. 7 (3): 157–70. doi:10.1177/2040620716636542. PMC 4872176Freely accessible. PMID 27247756. 
  10. ^ Roskoski R (2016). "Ibrutinib inhibition of Bruton protein-tyrosine kinase (BTK) in the treatment of B cell neoplasms". Pharmacological Research. 113 (Pt A): 395–408. doi:10.1016/j.phrs.2016.09.011. PMID 27641927. 
  11. ^ Cheah CY, Fowler NH (2016). "Idelalisib in the management of lymphoma". Blood. 128 (3): 331–6. doi:10.1182/blood-2016-02-702761. PMID 27252232. 
  12. ^ Scott IC, Scott DL (2014). "Spleen tyrosine kinase inhibitors for rheumatoid arthritis: where are we now?". Drugs. 74 (4): 415–22. doi:10.1007/s40265-014-0193-9. PMID 24610702. 
  13. ^ Blancato J, Graves A, Rashidi B, Moroni M, Tchobe L, Ozdemirli M, Kallakury B, Makambi KH, Marian C, Mueller SC (2014). "SYK allelic loss and the role of Syk-regulated genes in breast cancer survival". Plos One. 9 (2): e87610. doi:10.1371/journal.pone.0087610. PMC 3921124Freely accessible. PMID 24523870. 
  14. ^ a b Bertagnolo V, Marchisio M, Brugnoli F, Bavelloni A, Boccafogli L, Colamussi ML, Capitani S (April 2001). "Requirement of tyrosine-phosphorylated Vav for morphological differentiation of all-trans-retinoic acid-treated HL-60 cells". Cell Growth & Differentiation. 12 (4): 193–200. PMID 11331248. 
  15. ^ Lupher ML, Rao N, Lill NL, Andoniou CE, Miyake S, Clark EA, Druker B, Band H (December 1998). "Cbl-mediated negative regulation of the Syk tyrosine kinase. A critical role for Cbl phosphotyrosine-binding domain binding to Syk phosphotyrosine 323". The Journal of Biological Chemistry. 273 (52): 35273–81. doi:10.1074/jbc.273.52.35273. PMID 9857068. 
  16. ^ Melander F, Andersson T, Dib K (March 2003). "Fgr but not Syk tyrosine kinase is a target for beta 2 integrin-induced c-Cbl-mediated ubiquitination in adherent human neutrophils". The Biochemical Journal. 370 (Pt 2): 687–94. doi:10.1042/BJ20021201. PMC 1223185Freely accessible. PMID 12435267. 
  17. ^ Oda A, Ochs HD, Lasky LA, Spencer S, Ozaki K, Fujihara M, Handa M, Ikebuchi K, Ikeda H (May 2001). "CrkL is an adapter for Wiskott-Aldrich syndrome protein and Syk". Blood. 97 (9): 2633–9. doi:10.1182/blood.V97.9.2633. PMID 11313252. 
  18. ^ Ibarrola I, Vossebeld PJ, Homburg CH, Thelen M, Roos D, Verhoeven AJ (July 1997). "Influence of tyrosine phosphorylation on protein interaction with FcgammaRIIa". Biochimica et Biophysica Acta. 1357 (3): 348–58. doi:10.1016/S0167-4889(97)00034-7. PMID 9268059. 
  19. ^ Kim MK, Pan XQ, Huang ZY, Hunter S, Hwang PH, Indik ZK, Schreiber AD (January 2001). "Fc gamma receptors differ in their structural requirements for interaction with the tyrosine kinase Syk in the initial steps of signaling for phagocytosis". Clinical Immunology. 98 (1): 125–32. doi:10.1006/clim.2000.4955. PMID 11141335. 
  20. ^ Deckert M, Elly C, Altman A, Liu YC (April 1998). "Coordinated regulation of the tyrosine phosphorylation of Cbl by Fyn and Syk tyrosine kinases". The Journal of Biological Chemistry. 273 (15): 8867–74. doi:10.1074/jbc.273.15.8867. PMID 9535867. 
  21. ^ Chung J, Gao AG, Frazier WA (June 1997). "Thrombspondin acts via integrin-associated protein to activate the platelet integrin alphaIIbbeta3". The Journal of Biological Chemistry. 272 (23): 14740–6. doi:10.1074/jbc.272.23.14740. PMID 9169439. 
  22. ^ a b Ganju RK, Brubaker SA, Chernock RD, Avraham S, Groopman JE (June 2000). "Beta-chemokine receptor CCR5 signals through SHP1, SHP2, and Syk". The Journal of Biological Chemistry. 275 (23): 17263–8. doi:10.1074/jbc.M000689200. PMID 10747947. 
  23. ^ Saci A, Liu WQ, Vidal M, Garbay C, Rendu F, Bachelot-Loza C (May 2002). "Differential effect of the inhibition of Grb2-SH3 interactions in platelet activation induced by thrombin and by Fc receptor engagement". The Biochemical Journal. 363 (Pt 3): 717–25. doi:10.1042/0264-6021:3630717. PMC 1222524Freely accessible. PMID 11964172. 
  24. ^ Thome M, Duplay P, Guttinger M, Acuto O (June 1995). "Syk and ZAP-70 mediate recruitment of p56lck/CD4 to the activated T cell receptor/CD3/zeta complex". The Journal of Experimental Medicine. 181 (6): 1997–2006. doi:10.1084/jem.181.6.1997. PMC 2192070Freely accessible. PMID 7539035. 
  25. ^ Sidorenko SP, Law CL, Chandran KA, Clark EA (January 1995). "Human spleen tyrosine kinase p72Syk associates with the Src-family kinase p53/56Lyn and a 120-kDa phosphoprotein". Proceedings of the National Academy of Sciences of the United States of America. 92 (2): 359–63. doi:10.1073/pnas.92.2.359. PMC 42739Freely accessible. PMID 7831290. 
  26. ^ Sada K, Minami Y, Yamamura H (September 1997). "Relocation of Syk protein-tyrosine kinase to the actin filament network and subsequent association with Fak". European Journal of Biochemistry. 248 (3): 827–33. doi:10.1111/j.1432-1033.1997.00827.x. PMID 9342235. 
  27. ^ Dustin LB, Plas DR, Wong J, Hu YT, Soto C, Chan AC, Thomas ML (March 1999). "Expression of dominant-negative src-homology domain 2-containing protein tyrosine phosphatase-1 results in increased Syk tyrosine kinase activity and B cell activation". Journal of Immunology. 162 (5): 2717–24. PMID 10072516. 
  28. ^ Deckert M, Tartare-Deckert S, Couture C, Mustelin T, Altman A (December 1996). "Functional and physical interactions of Syk family kinases with the Vav proto-oncogene product". Immunity. 5 (6): 591–604. doi:10.1016/S1074-7613(00)80273-3. PMID 8986718. 
  29. ^ Song JS, Gomez J, Stancato LF, Rivera J (October 1996). "Association of a p95 Vav-containing signaling complex with the FcepsilonRI gamma chain in the RBL-2H3 mast cell line. Evidence for a constitutive in vivo association of Vav with Grb2, Raf-1, and ERK2 in an active complex". The Journal of Biological Chemistry. 271 (43): 26962–70. doi:10.1074/jbc.271.43.26962. PMID 8900182. 

Further reading[edit]

  • Turner M, Schweighoffer E, Colucci F, Di Santo JP, Tybulewicz VL (March 2000). "Tyrosine kinase SYK: essential functions for immunoreceptor signalling". Immunology Today. 21 (3): 148–54. doi:10.1016/S0167-5699(99)01574-1. PMID 10689303. 
  • Fruman DA, Satterthwaite AB, Witte ON (July 2000). "Xid-like phenotypes: a B cell signalosome takes shape". Immunity. 13 (1): 1–3. doi:10.1016/S1074-7613(00)00002-9. PMID 10933389. 
  • Yanagi S, Inatome R, Takano T, Yamamura H (November 2001). "Syk expression and novel function in a wide variety of tissues". Biochemical and Biophysical Research Communications. 288 (3): 495–8. doi:10.1006/bbrc.2001.5788. PMID 11676469. 
  • Tohyama Y, Yamamura H (2006). "Complement-mediated phagocytosis--the role of Syk". IUBMB Life. 58 (5-6): 304–8. doi:10.1080/15216540600746377. PMID 16754322. 
  • Schymeinsky J, Mócsai A, Walzog B (August 2007). "Neutrophil activation via beta2 integrins (CD11/CD18): molecular mechanisms and clinical implications". Thrombosis and Haemostasis. 98 (2): 262–73. doi:10.1160/th07-02-0156. PMID 17721605. 

External links[edit]